-Company waiting Priority Review for Enasidenib in Relapsed or Refractory AML with an IDH2 Mutation from the FDA (Due early August).
-Thier IDH1m (IVOSIDENIB) looks somewhat promising
- They are currently at 53.84 which is low given the above two points. NASDAQ:AGIO
